Your search history is turned on.
Date: April 16, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial NEW YORK, April 16, 2024 Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental...
Date: April 5, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
To All Applicable Exchanges and Securities Administrators Subject: Psyence Group Inc. (the "Issuer") Notice of Meeting and Record Date Dear Sir/Madam: Annual General and Special Meeting June 7, 2024 May 1, 2024 May 1, 2024 May 1, 2024 Common CA74449Q1063 No No No No Yours truly, Odyssey Trust Company as a...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Form51-102F3 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Item 2 Item 3 Item 4 Item 5 5.1 5.2 Item 6 Item 7 Name and Address of Company Psyence Group Inc. (the Company) 121 Richmond Street West Penthouse Suite, 1300, Toronto ON M5H 2K1, Canada Date of Material Change April 1, 2024 News Release A news ...
Date: March 26, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Psyence - Corporate Update [EGS Comments] (01333601-3).DOCX PSYENCE GROUP ANNOUNCES THE CLOSING OF THE PREVIOUSLY ANNOUNCED STRATEGIC RESTRUCRING OF ITS NON-CLINICAL BUSINESS TORONTO, March 26, 2024 -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its no...
Date: March 12, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study NEW YORK, March 12, 2024 Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health ...
Date: March 11, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Form51-102F3 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Psyence Group Inc. (the Company) 121 Richmond Street West Penthouse Suite, 1300, Toronto ON M5H 2K1, Canada Item 2 Date of Material Change March 11, 2024 Item 3 News Release A news release dated March 11, 2024 was distributed and su...
Psyence - Corporate Update [EGS Comments] (01333601-3).DOCX PSYENCE GROUP PROVIDES CORPORATE UPDATE FOLLOWING SUCCESSFUL SPAC SPIN OUT OF THERAPEUTIC DIVISION TORONTO, March 11, 2024 -- Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination of i...
Date: February 28, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Warwick Corden-Lloyd, Chief Financial Officer of Psyence Group Inc,, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Psyence Group Inc. (the issuer) for the interim period ended December 31, 202...
1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Dr. Neil Maresky, CEO, Psyence Group Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Psyence Group Inc. (the issuer) for the interim period ended December 31, 2023. 2. No misrepresentat...
Microsoft Word - PSYENCE GROUP INC. MDA for the three and nine months period ended December 31, 2023 Psyence Group Inc. Management Discussion & Analysis (MD&A) for the three months and nine months ended December 31, 2023 Date of the MD&A: February 28, 2024 Registration number: 1074709 ...